Trial reportTranslational psychiatry2019
Can targeted metabolomics predict depression recovery? Results from the CO-MED trial.
Trial report in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Metabolomics in Depression: What We Learn from Preclinical and Clinical Evidences.Molecular neurobiology · 2025Pooled it
- Associations of depression status with plasma levels of candidate lipid and amino acid metabolites: a meta-analysis of individual data from three independent samples of US postmenopausal women.Molecular psychiatry · 2021Pooled it
- Prognostic Biomarkers and Precision Psychiatry: A Review of the Available Evidence.Biomedicines · 2026Review
- Resistant Potato Starch Supplementation Increases the Serum Levels of Choline and Sphingomyelins Without Affecting Trimethylamine Oxide Levels.Metabolites · 2025Article
- Validated metabolomic biomarkers in psychiatric disorders: a narrative review.Molecular medicine (Cambridge, Mass.) · 2025Review
- The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.CNS neuroscience & therapeutics · 2025Article
- Article
- Biomarkers: The Key to Enhancing Deep Brain Stimulation Treatment for Psychiatric Conditions.Brain sciences · 2024Review
- Acylcarnitines are associated with lower depressive symptomatology in a mainland puerto rican cohort.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Observational
- Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study.CNS neuroscience & therapeutics · 2022Article
- Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder.Journal of personalized medicine · 2022Article
- Review
- Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder.Frontiers in pharmacology · 2022Article
- Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.Translational psychiatry · 2021Article
- Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report.Communications biology · 2021Article
- Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence.Translational psychiatry · 2021Article
- Development and Internal Validation of a Novel Model to Identify Inflammatory Biomarkers of a Response to Escitalopram in Patients With Major Depressive Disorder.Frontiers in psychiatry · 2021Article
- Metabolomics in Radiation Biodosimetry: Current Approaches and Advances.Metabolites · 2020Review
- Metabolomic Biomarkers in Anxiety Disorders.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolomics is a developing and promising tool for exploring molecular pathways underlying symptoms of depression and predicting depression recovery. The AbsoluteIDQ™ p180 kit was used to investigate whether plasma metabolites (sphingomyelins, lysophosphatidylcholines, phosphatidylcholines, and acylcarnitines) from a subset of participants in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial could act as predictors or biologic correlates of depression recovery. Participants in this trial were assigned to one of three pharmacological treatment arms: escitalopram monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination. Plasma was collected at baseline in 159 participants and again 12 weeks later at study exit in 83 of these participants. Metabolite concentrations were measured and combined with clinical and sociodemographic variables using the hierarchical lasso to simultaneously model whether specific metabolites are particularly informative of depressive recovery. Increased baseline concentrations of phosphatidylcholine C38:1 showed poorer outcome based on change in the Quick Inventory of Depressive Symptoms (QIDS). In contrast, an increased ratio of hydroxylated sphingomyelins relative to non-hydroxylated sphingomyelins at baseline and a change from baseline to exit suggested a better reduction of symptoms as measured by QIDS score. All metabolite-based models performed superior to models only using clinical and sociodemographic variables, suggesting that metabolomics may be a valuable tool for predicting antidepressant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.